Tags

Type your tag names separated by a space and hit enter

Skin and soft tissue infections in intercontinental travellers and the import of multi-resistant Staphylococcus aureus to Europe.
Clin Microbiol Infect. 2015 Jun; 21(6):567.e1-10.CM

Abstract

Staphylococcus aureus is emerging globally. Treatment of infections is complicated by increasing antibiotic resistance. We collected clinical data and swabs of returnees with skin and soft tissue infections (SSTI) at 13 travel-clinics in Europe (www.staphtrav.eu). Sixty-two percent (196/318) SSTI patients had S. aureus-positive lesions, of which almost two-thirds (122/196) were Panton-Valentine leukocidin (PVL) positive. PVL was associated with disease severity, including hospitalization for SSTI (OR 5.2, 95% CI 1.5-18.2). In returnees with SSTI, longer travel and more intense population contact were risk factors for nasal colonization with PVL-positive S. aureus. Imported S. aureus frequently proved resistant to trimethoprim-sulfamethoxazole (21%), erythromycin (21%), tetracycline (20%), ciprofloxacin (13%), methicillin (12%) and clindamycin (8%). Place of exposure was significantly (p < 0.05) associated with predominant resistance phenotypes and spa genotypes: Latin America (methicillin; t008/CC24/304), Africa (tetracycline, trimethoprim-sulfamethoxazole; t084/CC84, t314/singleton, t355/CC355), South Asia (trimethoprim-sulfamethoxazole, ciprofloxacin; t021/CC21/318), South-East Asia (clindamycin; t159/CC272). USA300-like isolates accounted for 30% of all methicillin-resistant S. aureus imported to Europe and were predominantly (71%) acquired in Latin America. Multi-resistance to non-β-lactams were present in 24% of imports and associated with travel to South Asia (ORcrude 5.3, 95% CI 2.4-11.8), even after adjusting for confounding by genotype (ORadjusted 3.8, 95% 1.5-9.5). Choosing randomly from compounds recommended for the empiric treatment of severe S. aureus SSTI, 15% of cases would have received ineffective antimicrobial therapy. These findings call for the development of regionally stratified guidance on the antibiotic management of severe imported S. aureus disease and put the infected and colonized traveller at the centre of interventions against the global spread of multi-resistant S. aureus.

Authors+Show Affiliations

Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University Hospital, Heidelberg, Germany; Institute of Tropical Medicine, Eberhard Karls Universität, Tübingen, Germany.Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, Spandauer Damm, Berlin, Germany.Tropenklinik, Paul-Lechler-Krankenhaus, Tübingen, Germany.Instituut voor Tropische Ziekten, Havenziekenhuis, TG Rotterdam, The Netherlands.Centre of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.Service de Maladies Infectieuses et Tropicales, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.Missionsärztliche Klinik, Würzburg, Germany.Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.Abteilung für Infektions- und Tropenmedizin der Ludwig-Maximilians-Universität, München, Germany.ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.Missionsärztliche Klinik, Würzburg, Germany.Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland; Epidemiology, Biostatistics and Prevention Institute, University of Zürich, Zürich, Switzerland.Service de Maladies Infectieuses et Tropicales, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.Centre of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.Tropenklinik, Paul-Lechler-Krankenhaus, Tübingen, Germany.Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, Spandauer Damm, Berlin, Germany.Institute of Tropical Medicine, Eberhard Karls Universität, Tübingen, Germany; Institute of Public Health, Unit of Epidemiology and Biostatistics, Heidelberg University Hospital, Heidelberg, Germany. Electronic address: philipp.zanger@uni-heidelberg.de.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25753191

Citation

Nurjadi, D, et al. "Skin and Soft Tissue Infections in Intercontinental Travellers and the Import of Multi-resistant Staphylococcus Aureus to Europe." Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 21, no. 6, 2015, pp. 567.e1-10.
Nurjadi D, Friedrich-Jänicke B, Schäfer J, et al. Skin and soft tissue infections in intercontinental travellers and the import of multi-resistant Staphylococcus aureus to Europe. Clin Microbiol Infect. 2015;21(6):567.e1-10.
Nurjadi, D., Friedrich-Jänicke, B., Schäfer, J., Van Genderen, P. J., Goorhuis, A., Perignon, A., Neumayr, A., Mueller, A., Kantele, A., Schunk, M., Gascon, J., Stich, A., Hatz, C., Caumes, E., Grobusch, M. P., Fleck, R., Mockenhaupt, F. P., & Zanger, P. (2015). Skin and soft tissue infections in intercontinental travellers and the import of multi-resistant Staphylococcus aureus to Europe. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 21(6), e1-10. https://doi.org/10.1016/j.cmi.2015.01.016
Nurjadi D, et al. Skin and Soft Tissue Infections in Intercontinental Travellers and the Import of Multi-resistant Staphylococcus Aureus to Europe. Clin Microbiol Infect. 2015;21(6):567.e1-10. PubMed PMID: 25753191.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Skin and soft tissue infections in intercontinental travellers and the import of multi-resistant Staphylococcus aureus to Europe. AU - Nurjadi,D, AU - Friedrich-Jänicke,B, AU - Schäfer,J, AU - Van Genderen,P J J, AU - Goorhuis,A, AU - Perignon,A, AU - Neumayr,A, AU - Mueller,A, AU - Kantele,A, AU - Schunk,M, AU - Gascon,J, AU - Stich,A, AU - Hatz,C, AU - Caumes,E, AU - Grobusch,M P, AU - Fleck,R, AU - Mockenhaupt,F P, AU - Zanger,P, Y1 - 2015/01/28/ PY - 2014/11/16/received PY - 2014/12/28/revised PY - 2015/01/16/accepted PY - 2015/3/11/entrez PY - 2015/3/11/pubmed PY - 2016/8/3/medline KW - Drug resistance KW - Panton–Valentine leukocidin KW - emerging communicable diseases KW - methicillin-resistant Staphylococcus aureus KW - molecular epidemiology KW - risk factors KW - sentinel surveillance KW - staphylococcal skin infections KW - travel medicine KW - trimethoprim-sulfamethoxazole combination SP - 567.e1 EP - 10 JF - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JO - Clin. Microbiol. Infect. VL - 21 IS - 6 N2 - Staphylococcus aureus is emerging globally. Treatment of infections is complicated by increasing antibiotic resistance. We collected clinical data and swabs of returnees with skin and soft tissue infections (SSTI) at 13 travel-clinics in Europe (www.staphtrav.eu). Sixty-two percent (196/318) SSTI patients had S. aureus-positive lesions, of which almost two-thirds (122/196) were Panton-Valentine leukocidin (PVL) positive. PVL was associated with disease severity, including hospitalization for SSTI (OR 5.2, 95% CI 1.5-18.2). In returnees with SSTI, longer travel and more intense population contact were risk factors for nasal colonization with PVL-positive S. aureus. Imported S. aureus frequently proved resistant to trimethoprim-sulfamethoxazole (21%), erythromycin (21%), tetracycline (20%), ciprofloxacin (13%), methicillin (12%) and clindamycin (8%). Place of exposure was significantly (p < 0.05) associated with predominant resistance phenotypes and spa genotypes: Latin America (methicillin; t008/CC24/304), Africa (tetracycline, trimethoprim-sulfamethoxazole; t084/CC84, t314/singleton, t355/CC355), South Asia (trimethoprim-sulfamethoxazole, ciprofloxacin; t021/CC21/318), South-East Asia (clindamycin; t159/CC272). USA300-like isolates accounted for 30% of all methicillin-resistant S. aureus imported to Europe and were predominantly (71%) acquired in Latin America. Multi-resistance to non-β-lactams were present in 24% of imports and associated with travel to South Asia (ORcrude 5.3, 95% CI 2.4-11.8), even after adjusting for confounding by genotype (ORadjusted 3.8, 95% 1.5-9.5). Choosing randomly from compounds recommended for the empiric treatment of severe S. aureus SSTI, 15% of cases would have received ineffective antimicrobial therapy. These findings call for the development of regionally stratified guidance on the antibiotic management of severe imported S. aureus disease and put the infected and colonized traveller at the centre of interventions against the global spread of multi-resistant S. aureus. SN - 1469-0691 UR - https://www.unboundmedicine.com/medline/citation/25753191/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S1198-743X(15)00221-9 DB - PRIME DP - Unbound Medicine ER -